Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Anthracycline-Induced Cardiotoxicity in Breast Cancer
NCT06711185Phase 3Recruiting
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anthracycline-induced cardiotoxicity comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in Left Ventricle Ejection Fraction at 36 weeks. Started Jan 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT06711185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711185.